Who
Mark A. Weinberger
Director
Company insider
Files Form 4 as: Director, MetLife; Director, Johnson & Johnson; Director, JP Morgan Chase & Co; Director, Accelerate Acquisition.
In numbers
- Trades disclosed
- 60
- Buys
- 1
- Sells
- 0
- Bought
- $147K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 21 Aug 2019
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Dec 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | —544 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | —587 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | —587 at $0.00 | filing |
| 23 Apr 2026filed 27 Apr 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —975 at $0.00 | filing |
| 23 Apr 2026filed 27 Apr 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —975 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | —721 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | —721 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | JPM JP Morgan Chase & CoMoney-centre banks | SEC FORM 4 Code A | $280K913.525 at $306.51 | filing |
| 20 Jan 2026filed 22 Jan 2026 | JPM JP Morgan Chase & CoMoney-centre banks | SEC FORM 4 Code A | $280K913.53 at $306.51 | filing |
| 2 Jan 2026filed 6 Jan 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | —639 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | MET MetLifeInsurance | SEC FORM 4 Code A | —639 at $0.00 | filing |
| 1 Oct 2025filed 3 Oct 2025 | MET MetLifeInsurance | SEC FORM 4 Code A | —534 at $0.00 | filing |
| 17 Jun 2025filed 20 Jun 2025 | MET MetLifeInsurance | SEC FORM 4 Code A | —562 at $0.00 | filing |
| 24 Apr 2025filed 28 Apr 2025 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,316 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | MET MetLifeInsurance | SEC FORM 4 Code A | —540 at $0.00 | filing |
| 21 Jan 2025filed 23 Jan 2025 | JPM JP Morgan Chase & CoMoney-centre banks | SEC FORM 4 Code A | $265K1,011.93 at $261.88 | filing |
| 2 Jan 2025filed 6 Jan 2025 | MET MetLifeInsurance | SEC FORM 4 Code A | —535 at $0.00 | filing |
| 12 Dec 2024filed 12 Dec 2024 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Bought | $147K1,000 at $147.22 | filing |
| 1 Oct 2024filed 3 Oct 2024 | MET MetLifeInsurance | SEC FORM 4 Code A | —535 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | MET MetLifeInsurance | SEC FORM 4 Code A | —627 at $0.00 | filing |
News
Johnson & Johnson's Dividend Machine Is Running. Can Earnings Keep Up?JNJ · insidermonkey.com · 19 Oct 2026Johnson & Johnson Reports Positive 48-week Data From TREMFYA Study In Crohn's With Perianal FistulaJNJ · rttnews.com · 19 Oct 2026Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19JNJ · equitybulls.com · 18 Oct 2026
0 headlines in the last 90 days name Mark A. Weinberger; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.